Judy Dering

5.5k total citations · 1 hit paper
41 papers, 3.6k citations indexed

About

Judy Dering is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Judy Dering has authored 41 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 22 papers in Oncology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Judy Dering's work include HER2/EGFR in Cancer Research (10 papers), PI3K/AKT/mTOR signaling in cancer (7 papers) and Ovarian cancer diagnosis and treatment (6 papers). Judy Dering is often cited by papers focused on HER2/EGFR in Cancer Research (10 papers), PI3K/AKT/mTOR signaling in cancer (7 papers) and Ovarian cancer diagnosis and treatment (6 papers). Judy Dering collaborates with scholars based in United States, United Kingdom and Canada. Judy Dering's co-authors include Dennis J. Slamon, Richard S. Finn, Charles Ginther, Amrita Desai, Ondrej Kalous, Dylan Conklin, Mohammad Atefi, David J. Cohen, Camilla Fowst and Isan Chen and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Judy Dering

41 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

2009 1.0k citations Richard S. Finn, Judy Dering et al. Breast Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Judy Dering United States	23	2.2k	1.5k	1.3k	902	343	41	3.6k
Knut Engels Germany	30	2.1k 1.0×	1.6k 1.1×	462 0.4×	908 1.0×	172 0.5×	84	3.8k
Stacy Moulder United States	29	2.7k 1.2×	1.7k 1.2×	2.6k 1.9×	1.6k 1.8×	156 0.5×	70	4.7k
Mark R. Lackner United States	32	1.8k 0.8×	2.6k 1.7×	988 0.8×	1.5k 1.7×	90 0.3×	82	4.4k
Mónica Arnedos France	25	1.6k 0.7×	1.4k 0.9×	1.0k 0.8×	1.2k 1.4×	73 0.2×	90	3.1k
Roland Penzel Germany	40	1.8k 0.8×	1.7k 1.1×	1.5k 1.1×	1.3k 1.4×	106 0.3×	134	4.4k
Drew Rasco United States	33	2.4k 1.1×	1.7k 1.2×	980 0.7×	516 0.6×	123 0.4×	192	4.1k
Thomas Januario United States	12	2.1k 1.0×	3.4k 2.3×	1.3k 1.0×	894 1.0×	91 0.3×	19	4.8k
Nina N. Nupponen Finland	35	999 0.5×	2.2k 1.5×	1.4k 1.1×	1.1k 1.2×	127 0.4×	64	4.5k
Kerry Fenwick United Kingdom	38	2.2k 1.0×	2.8k 1.9×	1.1k 0.8×	1.9k 2.1×	152 0.4×	60	4.9k
Anna Berkenblit United States	26	1.4k 0.6×	1.6k 1.1×	1.3k 1.0×	710 0.8×	445 1.3×	57	3.2k

Countries citing papers authored by Judy Dering

Since Specialization

Citations

This map shows the geographic impact of Judy Dering's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judy Dering with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judy Dering more than expected).

Fields of papers citing papers by Judy Dering

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judy Dering. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judy Dering. The network helps show where Judy Dering may publish in the future.

Co-authorship network of co-authors of Judy Dering

This figure shows the co-authorship network connecting the top 25 collaborators of Judy Dering. A scholar is included among the top collaborators of Judy Dering based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judy Dering. Judy Dering is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zoeller, Jason J., Michael F. Press, Laura M. Selfors, et al.. (2021). Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy. PLoS ONE. 16(5). e0251163–e0251163. 8 indexed citations

Winterhoff, Boris, Habib Hamidi, Chen Wang, et al.. (2016). Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures. Gynecologic Oncology. 141(1). 95–100. 40 indexed citations

Konecny, Gottfried E., Chen Wang, Habib Hamidi, et al.. (2014). Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian Cancer. JNCI Journal of the National Cancer Institute. 106(10). 267 indexed citations

Finn, Richard S., Michael F. Press, Judy Dering, et al.. (2013). Quantitative ER and PgR Assessment as Predictors of Benefit from Lapatinib in Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer. Clinical Cancer Research. 20(3). 736–743. 20 indexed citations

Garon, Edward B., Richard S. Finn, Habib Hamidi, et al.. (2013). The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth. Molecular Cancer Therapeutics. 12(6). 890–900. 56 indexed citations

Cheon, Dong‐Joo, Yunguang Tong, Myung‐Shin Sim, et al.. (2013). A Collagen-Remodeling Gene Signature Regulated by TGF-β Signaling Is Associated with Metastasis and Poor Survival in Serous Ovarian Cancer. Clinical Cancer Research. 20(3). 711–723. 265 indexed citations

Kalous, Ondrej, Dylan Conklin, Amrita Desai, et al.. (2013). AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53. Breast Cancer Research and Treatment. 141(3). 397–408. 22 indexed citations

Finn, Richard S., Alexey Aleshin, Judy Dering, et al.. (2013). Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro. Hepatology. 57(5). 1838–1846. 43 indexed citations

Karlan, Beth Y., Judy Dering, Christine Walsh, et al.. (2013). POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer. Gynecologic Oncology. 132(2). 334–342. 75 indexed citations

10.

Garon, Edward B., Richard J. Pietras, Richard S. Finn, et al.. (2013). Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 8(3). 270–278. 47 indexed citations

11.

Finn, Richard S., Danyun Zhao, Lee Anderson, et al.. (2012). Abstract 3858: Gains in FGF19 are predictive of response to the fibroblast growth factor receptor (FGFR) small molecule tyrosine kinase inhibitor BGJ 398 in vitro. Cancer Research. 72(8_Supplement). 3858–3858. 13 indexed citations

12.

Garon, Edward B., Richard S. Finn, Wylie Hosmer, et al.. (2010). Identification of Common Predictive Markers of In vitro Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non–Small Cell Lung Cancer Cell Lines. Molecular Cancer Therapeutics. 9(7). 1985–1994. 49 indexed citations

13.

Finn, Richard S., Michael F. Press, Judy Dering, et al.. (2009). Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer. Journal of Clinical Oncology. 27(24). 3908–3915. 144 indexed citations

14.

Finn, Richard S., Judy Dering, Dylan Conklin, et al.. (2009). PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Research. 11(5). R77–R77. 1044 indexed citations breakdown →

15.

Cohen, Brenda, et al.. (2009). Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer. Breast Cancer Research and Treatment. 123(1). 113–124. 131 indexed citations

16.

Konecny, Gottfried E., Rickard Glas, Judy Dering, et al.. (2009). Activity of the multikinase inhibitor dasatinib against ovarian cancer cells. British Journal of Cancer. 101(10). 1699–1708. 81 indexed citations

17.

Leo, Angelo Di, Henry Gómez, Zeba Aziz, et al.. (2008). Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer. Journal of Clinical Oncology. 26(34). 5544–5552. 345 indexed citations

18.

Konecny, Gottfried E., Natarajan Venkatesan, Guangen Yang, et al.. (2008). Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. British Journal of Cancer. 98(6). 1076–1084. 92 indexed citations

19.

Finn, Richard S., Judy Dering, Charles Ginther, et al.. (2007). Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Research and Treatment. 105(3). 319–326. 330 indexed citations

20.

Wilson, Cindy, Elaina Cajulis, Jennifer L. Green, et al.. (2005). HER-2 overexpression differentially alters transforming growth factor-β responses in luminal versus mesenchymal human breast cancer cells. Breast Cancer Research. 7(6). R1058–79. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact